Guizhou Yibai Pharmaceutical Co Ltd
600594
Company Profile
Business description
Guizhou Yibai Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical products in China. Its products include tumor, cardio-cerebral vascular, respiratory system, anti-rheumatic, digestive system, pediatric, gynecological, andrological, anti-infection, anti-inflammatory, analgesic, tonic, and other drugs.
Contact
No. 220-1 Baiyun Avenue
GuiyangGuizhou550008
CHNT: +86 85147055908223
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
5,261
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,816.40 | 58.90 | -0.66% |
| CAC 40 | 7,753.44 | 12.77 | -0.16% |
| DAX 40 | 24,040.88 | 19.41 | -0.08% |
| Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
| FTSE 100 | 8,943.71 | 5.39 | 0.06% |
| HKSE | 24,544.77 | 45.35 | -0.18% |
| NASDAQ | 20,677.80 | 37.47 | 0.18% |
| Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
| NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
| S&P 500 | 6,243.76 | 24.80 | -0.40% |
| S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
| SSE Composite Index | 3,503.78 | 1.22 | -0.03% |